The role of COX-2/PGE2 in gossypol-induced apoptosis of colorectal carcinoma cells

Journal of Cellular Physiology

Volumn 227, Issue 8, 2012, Pages 3128-3137

  Chien, Chih Chiang ^a,b   Ko, Ching Huai ^b,c   Shen, Shing Chuan ^b   Yang, Liang Yo ^b   Chen, Yen Chou ^b,d  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 1 ACETYL 2 (8 CHLORO 10,11 DIHYDRODIBENZ[B,F][1,4]OXAZEPINE 10 CARBONYL)HYDRAZINE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ACETYLSALICYLIC ACID; BUTAPROSTOL; CASPASE 3; CYCLOOXYGENASE 2; DICLOFENAC; DNA; GOSSYPOL; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN D2; PROSTAGLANDIN E1 ALCOHOL; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN J2; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROTEIN BCL 2; PROTEIN MCL 1; SMALL INTERFERING RNA; STAUROSPORINE; SULPROSTOL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL PROTECTION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; T LYMPHOCYTE;

APOPTOSIS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GOSSYPOL; HT29 CELLS; HUMANS; PHORBOL ESTERS; PROTEIN KINASE INHIBITORS;

EID: 84860464663     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.23067     Document Type: Article

References (43)

1. Bai XM, Jiang H, Ding JX, Peng T, Ma J, Wang YH, Zhang L, Zhang H, Leng J. 2009. Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells. Life Sci 86: 214-223.
2. Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee J, Chen J, Wang S. 2005. Bradford, Carol R. Carey, Thomas E. 2005. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: Role of wild-type p53 and Bcl-xL. Mol Cancer Ther 4: 1096-1104.
3. Castellone MD, Teramoto H, Gutkind JS. 2006. Cyclooxygenase-2 and colorectal cancer chemoprevention: The beta-catenin connection. Cancer Res 66: 11085-11088.
4. Chang JS, Hsu YL, Kuo PL, Chiang LC, Lin CC. 2004. Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line. Clin Exp Pharmacol Physiol 31: 716-722.
5. Chow JM, Shen SC, Wu CY, Chen YC. 2006. 12-O-Tetradecanoylphorbol 13-acetate prevents baicalein-induced apoptosis via activation of protein kinase C and JNKs in human leukemia cells. Apoptosis 11: 1999-2011.
6. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. 1994. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188.
7. Gonzalez-Guerrico AM, Kazanietz MG. 2005. Phorbol ester-induced apoptosis in prostate cancer cells via autocrine activation of the extrinsic apoptotic cascade: A key role for protein kinase C delta. J Biol Chem 280: 38982-38991.
8. 2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386.
9. Guruswamy S, Rao CV. 2009. Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention. Int J Oncol 35: 1037-1043.
10. Han C, Michalopoulos GK, Wu T. 2006. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 207: 261-270.
11. Hu YF, Change CJ, Brueggemeier RW, Lin YC. 1994. Presence of antitumor activities in the milk collected from gossypol-treated dairy cows. Cancer Lett 87: 17-23.
12. Huang X, Heyman M, Nath S, Castagna M, Desjeux J. 1995. Distinct signaling mediates chloride secretion induced by tumor promoter bile-salts and phorbol esters in human colonic cells. Int J Oncol 6: 1159-1163.
13. Huang YW, Wang LS, Dowd MK, Wan PJ, Lin YC. 2009. (-)-Gossypol reduces invasiveness in metastatic prostate cancer cells. Anticancer Res 29: 2179-2188.
14. Hwang JT, Kim YM, Surh YJ, Baik HW, Lee SK, Ha J, Park OJ. 2006. Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells. Cancer Res 66: 10057-10063.
15. Janero DR, Burghardt B. 1988. Protection of rat myocardial phospholipid against peroxidative injury through superoxide- (xanthine oxidase)-dependent, iron-promoted fenton chemistry by the male contraceptive gossypol. Biochem Pharmacol 37: 3335-3342.
16. Kang MH, Reynolds CP. 2009. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15: 1126-1132.
17. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K. 2003. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 24: 985-990.
18. Kawamori T, Kitamura T, Watanabe K, Uchiya N, Maruyama T, Narumiya S, Sugimura T, Wakabayashi K. 2005. Prostaglandin E receptor subtype EP(1) deficiency inhibits colon cancer development. Carcinogenesis 26: 353-357.
19. Ko CH, Shen SC, Yang LY, Lin CW, Chen YC. 2007. Gossypol reduction of tumor growth through ROS-dependent mitochondria pathway in human colorectal carcinoma cells. Int J Cancer 121: 1670-1679.
20. Kojima T, Fuchimoto J, Yamaguchi H, Ito T, Takasawa A, Ninomiya T, Kikuchi S, Ogasawara N, Ohkuni T, Masaki T, Hirata K, Himi T, Sawada N. 2010. c-Jun N-terminal kinase is largely involved in the regulation of tricellular tight junctions via tricellulin in human pancreatic duct epithelial cells. J Cell Physiol 225: 720-733.
21. Leung E, McArthur D, Morris A, Williams N. 2008. Cyclooxygenase-2 inhibition prevents migration of colorectal cancer cells to extracellular matrix by down-regulation of matrix metalloproteinase-2 expression. Dis Colon Rectum 51: 342-347.
22. Lin TS, Schinazi RF, Zhu J, Birks E, Carbone R, Si Y, Wu K, Huang L, Prusoff WH. 1993. Anti-HIV-1 activity and cellular pharmacology of various analogs of gossypol. Biochem Pharmacol 46: 251-255.
23. Lin CW, Shen SC, Chien CC, Yang LY, Shia LT, Chen YC. 2010. 12-O-Tetradecanoylphorbol-13-acetate-induced invasion/migration of glioblastoma cells through activating PKCalpha/ERK/NF-kappaB-dependent MMP-9 expression. J Cell Physiol 225: 472-481.
24. Masuda Y, Yoda M, Ohizumi H, Aiuchi T, Watabe M, Nakajo S, Nakaya K. 1997. Activation of protein kinase C prevents induction of apoptosis by geranylgeraniol in human leukemia HL60 cells. Int J Cancer 71: 691-697.
25. Moon DO, Choi YH, Moon SK, Kim WJ, Kim GY. 2011. Gossypol decreases tumor necrosis factor-α-induced intercellular adhesion molecule-1 expression via suppression of NF-κB activity. Food Chem Toxicol 49: 999-1005.
26. Moreira L, Castells A. 2010. Cyclooxygenase as a target for colorectal cancer chemoprevention. Curr Drug Targets; Dec 15. [Epub ahead of print].
27. Namasivayam N. 2011. Chemoprevention in experimental animals. Ann N Y Acad Sci 1215: 60-71.
28. Pang X, Wu Y, Wu Y, Lu B, Chen J, Wang J, Yi Z, Qu W, Liu M. 2011. (-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis. Mol Cancer Ther 10: 795-805.
29. Philipose S, Konya V, Sreckovic I, Marsche G, Lippe IT, Peskar BA, Heinemann A, Schuligoi R. 2010. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol 30: 2416-2423.
30. Samadder NJ, Mukherjee B, Huang SC, Ahn J, Rennert HS, Greenson JK, Rennert G, Gruber SB. 2010. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer 117: 1640-1648.
31. Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T, Sugimoto Y, Negishi M, Narumiya S, Sugimura T, Wakabayashi K. 2004. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 53: 1151-1158.
32. Sung B, Ravindran J, Prasad S, Pandev MK, Aggarwal BB. 2010. Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL. J Biol Chem 285: 35418-35427.
33. Swamy MV, Cooma I, Patlolla JM, Simi B, Reddy BS, Rao CV. 2004. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer prevention and treatment. Mol Cancer Ther 3: 215-221.
34. Teng CS, Vilagrasa X. 1998. Biphasic c-Myc protein expression during gossypol-induced apoptosis in rat spermatocytes. Contraception 57: 117-123.
35. Timoshenko AV, Chakraborty C, Wagner GF, Lala PK. 2006. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 94: 1154-1163.
36. Tseng CS. 1995. Gossypol-induced apoptotic DNA fragmentation correlates with inhibited protein kinase C activity in spermatocytes. Contraception 52: 385-395.
37. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ, Cohen GM. 2009. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 16: 1030-1039.
38. Voss V, Senft C, Lang V, Ronellenfitsh MW, Steinbach JP, Seifert V, Kogel D. 2010. The Pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res 8: 1002-1016.
39. Wang D, Dubolis RN. 2010. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29: 781-788.
40. Xiao H, Zhang Q, Lin Y, Reddy BS, Yang CS. 2008. Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 122: 2115-2124.
41. Yang Z, Xiao H, Jin H, Koo PT, Tsang DJ, Yang CS. 2010. Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells. Int J Cancer 126: 852-863.
42. Zhang M, Liu H, Guo R, Ling Y, Wu X, Li B, Roller PP, Wang S, Yang D. 2003. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol 66: 93-103.
43. Zhuang S, Demirs JT, Kochevar IE. 2001. Protein kinase C inhibits singlet oxygen-induced apoptosis by decreasing caspase-8 activation. Oncogene 20: 6764-6776.